New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
11:09 EDTGNC, FTNT, MBI, LL, RDN, PSEC, TWTR, LO, SD, SRPTOptions with increasing implied volatility
Options with increasing implied volatility: LL SRPT TWTR MBI SD PSEC FTNT LO RDN GNC
News For LL;SRPT;TWTR;MBI;SD;PSEC;FTNT;LO;RDN;GNC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
August 21, 2015
13:38 EDTTWTRGoogle says brings tweets to mobile Google search app, desktop
In May, Google announced that it was bringing Tweets to Google Search on mobile devices. The company today updated the blog entry to say that it has "extended this to the desktop now, too, and in English everywhere." Reference Link
11:13 EDTTWTRStocks with call strike movement; AMZN TWTR
Subscribe for More Information
10:36 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: PTCT UVXY VIX VXX SVXXY SRPT TZA UPRO VNR SPXU
10:00 EDTTWTRTwitter volatility increases
Subscribe for More Information
09:59 EDTTWTRTwitter rises, levels to watch
Subscribe for More Information
09:34 EDTTWTRActive equity options trading on open
Active equity options trading on open: AAPL FB BAC NFLX DIS TSLA TWTR
08:32 EDTSRPTSarepta says FDA grants rare pediatric disease designation for Eteplirsen
Subscribe for More Information
August 20, 2015
16:48 EDTLLOn The Fly: Top stock stories for Thursday
Subscribe for More Information
13:26 EDTLLOn The Fly: Top stock stories at midday
Subscribe for More Information
11:49 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ACHN VIAV ZG RAD DIS ORCL SPY XLF OEX
11:12 EDTTWTRStocks with call strike movement; MU TWTR
Subscribe for More Information
10:42 EDTLLCantor upgrade gives embattled Lumber Liquidators a boost
Subscribe for More Information
10:00 EDTLLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:40 EDTLLLumber Liquidators upgraded to Buy from Hold at Cantor
Cantor Fitzgerald analyst Laura Champine upgraded Lumber Liquidators to Buy from Hold and raised her price target for shares to $18 from $15. The embattled wood flooring retailer closed yesterday down 75c to $14.21. The risk/reward scenario has become "much more appealing" with the down nearly 80% year-to-date, Champine tells investors in a research note. Appointing a chief compliance and legal officer with three decades of relevant experience should bring improved oversight, the analyst argues. Champine also raised her long-term gross margin assumptions after her recent store tour with senior management.
August 19, 2015
16:00 EDTTWTROptions Update; August 19, 2015
Subscribe for More Information
12:00 EDTTWTRTwitter falls, levels to watch
Subscribe for More Information
10:47 EDTRDNRadian Group management to meet with MKM Partners
Subscribe for More Information
09:33 EDTTWTRActive equity options trading on open
Active equity options trading on open: AAPL BAC FB BA TWTR NFLX WMT BABA
09:17 EDTSRPT'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
08:29 EDTSRPTFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use